
Dr Siegel on the Evaluation of Mezigdomide for R/R Myeloma
“Mezigdomide, which is the centerpiece of this [phase 1/2 CA057-003] trial, is a newer derivative of thalidomide, and for those uninformed, the thalidomide derivatives are probably the most important drugs that have been developed in myeloma over the …